Corbyn Investment Management Inc. MD Grows Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Corbyn Investment Management Inc. MD increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 93.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 28,931 shares of the medical equipment provider’s stock after purchasing an additional 13,963 shares during the quarter. Corbyn Investment Management Inc. MD’s holdings in Zimmer Biomet were worth $3,123,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ZBH. Crewe Advisors LLC purchased a new stake in shares of Zimmer Biomet in the first quarter valued at about $31,000. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet in the third quarter valued at about $28,000. Bangor Savings Bank purchased a new stake in Zimmer Biomet in the 3rd quarter valued at approximately $31,000. Family Firm Inc. acquired a new position in Zimmer Biomet during the 2nd quarter worth approximately $33,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $43,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ZBH has been the topic of a number of recent analyst reports. Oppenheimer dropped their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. Wells Fargo & Company upped their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Truist Financial raised their price objective on shares of Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a research note on Friday, November 1st. TD Cowen lowered their target price on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a research report on Friday, September 6th. Finally, UBS Group reduced their price target on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $123.22.

Zimmer Biomet Trading Up 3.4 %

Zimmer Biomet stock opened at $112.54 on Monday. The stock has a market cap of $22.40 billion, a PE ratio of 21.40, a P/E/G ratio of 2.07 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock has a 50-day moving average price of $106.28 and a 200 day moving average price of $109.98. Zimmer Biomet Holdings, Inc. has a 52 week low of $101.47 and a 52 week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the business posted $1.65 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.